Skip to main content
. 2021 Dec 30;1253:132308. doi: 10.1016/j.molstruc.2021.132308

Table 7.

Antileishmanial activity of ligand acids and synthesized complexes.

Compound % Inhibition
Dose Conc. (µM)
250 500 1000
HL1 17.04 ± 1.12 25.11 ± 1.89 85.13 ± 1.56
HL2 14.53 ± 1.23 16.38 ± 0.97 84.97 ± 1.32
1 89.91 ± 2.77 91.13 ± 2.78 91.99 ± 2.34
2 61.66 ± 2.53 76.90 ± 2.11 91.03 ± 2.71
HHS Vulnerability Disclosure